Lineage Cell Therapeutics Stock Analysis

Lineage Stock Analysis Notes

About 51.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 1.89. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Lineage Cell Therapeutics recorded a loss per share of 0.1. The entity had not issued any dividends in recent years. The firm had 3:1 split on the 31st of October 1997. Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California. Lineage Cell operates under Biotechnology classification in the United States and is traded on AMEX Exchange. It employs 57 people. To find out more about Lineage Cell Therapeutics contact MBA MA at 442 287 8990 or learn more at https://www.lineagecell.com.

Lineage Cell Therapeutics Investment Alerts

Lineage Cell Therapeutics Upcoming and Recent Events

Lineage Largest EPS Surprises

View All Earnings Estimates

Lineage Market Capitalization

The company currently falls under 'Small-Cap' category with a current market capitalization of 125.37 M.

Lineage Profitablity

Management Efficiency

Lineage Cell Therapeutics has return on total asset (ROA) of (0.1286) % which means that it has lost $0.1286 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3504) %, meaning that it created substantial loss on money invested by shareholders. Lineage Cell's management efficiency ratios could be used to measure how well Lineage Cell manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.52 in 2024. Return On Capital Employed is likely to drop to -0.31 in 2024. At this time, Lineage Cell's Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 65.7 M in 2024, whereas Total Current Assets are likely to drop slightly above 21.1 M in 2024.

Technical Drivers

As of the 29th of November, Lineage Cell secures the Standard Deviation of 5.7, mean deviation of 3.66, and Risk Adjusted Performance of (0.06). In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of Lineage Cell Therapeutics, as well as the relationship between them.

Lineage Cell Therapeutics Price Movement Analysis

Lineage Cell Therapeutics Insider Trading Activities

Lineage Cell Outstanding Bonds

Lineage Cell Predictive Daily Indicators

Lineage Cell Forecast Models

Lineage Cell's time-series forecasting models are one of many Lineage Cell's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Lineage Cell's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Stock analysis is the technique used by a trader or investor to examine and evaluate how Lineage Cell prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Lineage shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Lineage Cell. By using and applying Lineage Stock analysis, traders can create a robust methodology for identifying Lineage entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Lineage analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Lineage analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

Lineage Cell Therapeutics stock analysis indicators help investors evaluate how Lineage Cell stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Lineage Cell shares will generate the highest return on investment. By understating and applying Lineage Cell stock analysis, traders can identify Lineage Cell position entry and exit signals to maximize returns.

When running Lineage Cell's price analysis, check to measure Lineage Cell's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lineage Cell is operating at the current time. Most of Lineage Cell's value examination focuses on studying past and present price action to predict the probability of Lineage Cell's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lineage Cell's price. Additionally, you may evaluate how the addition of Lineage Cell to your portfolios can decrease your overall portfolio volatility.